Valuation
- Market cap
- 7,648,000
- Revenue TTM
- $890,000
- Net income TTM
- $-21,650,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -2,432.58%
- Debt to equity
- 0.19
Trading
- Volume
- 5,253,500
- Avg volume
- 628,210
- Day's range
- $0.74 – $0.86
- Shares out
- 9,060,000
- Stochastic %K
- 63%
- Beta
- 0.31
- Analysts
- Hold
- Price target
- $14.00
Company profile
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third...
Show more
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- Phone
- 49 6131 554 2860
- Website
- https://mainzbiomed.com
- Address
- Robert Koch Strasse 50, Mainz, Germany
Latest news
No headlines yet.
